J&J breathes some more life into plamotamab and CD28
Two Xencor approaches with questions around them receive the backing of Johnson & Johnson.
Non-genetic amyloidosis lives again, thanks to Darzalex and Astra
Interest in AL amyloidosis has been piqued by January’s approval of Darzalex, and today Astrazeneca bought out a company with a phase 3 asset.
Edesa finds a signal in severely ill Covid-19 patients
But other small biotechs are more advanced and still hope to play a role in the pandemic.
Esmo 2021 – Astra coasts towards a new lung cancer combo
Two new immuno-oncology mechanisms post encouraging data, giving a boost to small developers including Innate and Corvus.
Esmo 2021 – Keytruda challenges Jemperli and adjuvant melanoma
Glaxo’s anti-PD-1 MAb might not have a market niche to itself for long, while a separate trial could help Keytruda double its adjuvant melanoma potential.
Covid-19 research efforts slow
A few developers are still finding reasons to research novel pandemic treatments, though much of the ongoing work is focused on proven approaches.
Brii gets a Covid-19 antibody boost
But is there room for another antibody, given lacklustre sales and Regeneron’s dominance?
